ABSTRACT
Recent studies have demonstrated that phosphoinositide 3-kinases (PI3Ks) play a fundamental role in regulating myocardial contractility. However, even though α 1 -adrenergic receptor stimulation is known to activate PI3Ks, the impact of this pathway on the inotropic effects of alpha 1 -stimulation is unclear. Isolated rabbit ventricular myocytes were preincubated with the PI3K inhibitor wortmannin (WM, 0.1µmol/L)). The alpha 1 agonist phenylephrine (PE, 10 µmol/L) induced a significantly stronger increase in contractility in WMtreated versus control myocytes (Fractional shortening in % of resting cell length: 6.14+/-0.33%; n=26 versus 4.85+/-0.33%; n=26, P<0.05). Furthermore, pretreatment with WM significantly increased the positive inotropic effect of PE in intact muscle strips from rabbit hearts. Mechanistically, we demonstrate that in WM-treated myocytes PE increased phospholamban (PLN) phosphorylation and intracellular Ca 2+ transients to a significantly greater extent than in control myocytes. In summary, this is the first study to demonstrate that inhibition of PI3K by increasing PLN phosphorylation and Ca 2+ transients significantly improves contractility in alpha 1 -adrenergically stimulated myocardium. This may have clinical implications for the treatment of decreased cardiac function in acute heart failure.
INTRODUCTION
Phosphoinositide 3-kinases (PI3Ks) are a family of evolutionarily conserved lipid kinases that play a central role in the control of cell growth, proliferation, metabolism, apoptosis, membrane transport, and cell motility. Thus, PI3Ks regulate several physiological processes and are involved in the pathology of cancer, metabolic, inflammatory, and cardiovascular diseases (1) (2) (3) . In myocardium, PI3K activity is essential for both basal cell growth as well as adaptive (physiologic) and maladaptive (pathologic) hypertrophy (4) (5) (6) (7) (8) (9) . In this regard, the intensity and duration of Akt activation, a well characterized downstream target of PI3K, appear to determine the character of hypertrophy (8) (9) (10) .
Furthermore, PI3Ks control glucose and amino acid metabolism in the heart (11, 12) . By inhibiting apoptosis, activation of PI3Ks plays a crucial role in cardiac myocyte survival. PI3K activation decreases infarct size after transient ischemia and prevents cardiac myocytes from oxidative stress-induced apoptosis (13) (14) (15) .
Moreover, recent studies have demonstrated that PI3Ks play a fundamental role in regulating mechanotransduction and myocardial contractility (5, 11, 16, 17) . Cardiac-specific overexpression of IGF-1 receptor or IGF-1 infusion improve contractile function in mouse hearts by increasing PI3K activity (5, 16) . Consistently, knockout of insulin receptor results in reduced contractility (11) . On the other hand, PI3Ks reduce beta-adrenergically mediated elevation in cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) activity, thereby counteracting the positive inotropic effects of beta-adrenergic signaling (17) . Thus, modulating cardiac contractility by PI3Ks following insulin/IGF-1 and betaadrenergic receptor stimulation has been described. In this regard, there is now growing evidence that the effect of PI3K on contractility depends on the specific PI3K isoform. PI3Kalpha and PI3Kgamma are the two main isoforms expressed in cardiac myocytes. PI3Kalpha predominantly regulates heart growth, but also exerts positive inotropic effects, whereas PI3Kgamma negatively influences cardiac contractility (2, (17) (18) (19) (20) .
However, although alpha 1 -adrenergic agonists are also known to increase PI3K activity the impact of PI3Ks on the inotropic effects of alpha 1 -adrenergic stimulation is unclear (21) . In the present study we investigate the effects of PI3Ks on contractile function and intracellular Ca 2+ handling in alpha 1 -adrenergically stimulated myocardium. Since growing evidence indicates that PI3Ks might qualify as drug targets for the treatment of cardiovascular diseases, cancer, and inflammation, exact knowledge of the coupling between the different cell-surface receptors, PI3Ks, and effectors is essential to predict how PI3K inhibitors could ameliorate disease and whether they might interfere with vital processes. To inhibit PI3Ks, myocytes were preincubated with wortmannin (WM, Sigma-Aldrich, 0.1 µmol/L), a well established and widely used PI3K inhibitor, for 20 min. Since WM was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich), control myocytes were incubated with DMSO (highest final concentration of DMSO in all experiments: 0.1 mL/L). Both groups of myocytes (WM and control) were stimulated with the alpha 1 agonist phenylephrine (PE, 10 µmol/L). Shortening and [Ca 2+ ] i measurements were performed as reported previously (22, 23) . Briefly, myocytes were loaded with the Ca 2+ -sensitive dye indo-1/AM (10 µmol/L, Molecular Probes) to measure [Ca 2+ ] i . Fluorescence was excited at 360+/-5 nm using a 75 W xenon arc lamp (Ushio, Japan) on the stage of a Nikon Eclipse TE200-U inverted microscope. Emitted fluorescence was measured using photomultipliers (at 405+/-15 nm and 485+/-12.5 nm; IonOptix Corp., Milton, MA). From the raw fluorescence, the indo-1 ratio was calculated (405 nm/485 nm) after subtraction of autofluorescence. Myocytes were electrically fieldstimulated (voltage 25% above threshold) at 1 Hz and 37°C until myocyte shortening reached a steady state.
MATERIALS AND METHODS

3
Preparation and contractile testing of intact muscle strips
Rabbits were heparinized and anesthetized as described above. Hearts were rapidly excised and retrogradely perfused with a modified Krebs-Henseleit buffer solution containing (in mmol/L): Na + 140. -concentration was raised stepwise (0.25 mmol/L every 2 min) up to 1.25 mmol/L. Isometric contractions were elicited using electrical field stimulation (1 Hz, amplitude 3 to 5 V; stimulator Stim1, Scientific Instruments). The force transducer signals were amplified and analyzed using software custom-made on the LabVIEW ® platform (National Instruments, U.S.A.). After a stabilization phase (30 min), muscle strips were carefully stretched until diastolic resting tension reached a level of 2 mN/mm 2 . This reflects a physiological sarcomere length below L max (sarcomere length at which developed force is maximum) and produces the most stable long-time performance of a preparation (24) .
To inhibit PI3Ks, the bath solution was supplemented with WM (0.1 µmol/L) or DMSO solution without WM. After 40 min of preincubation with WM, both groups of muscle strips (WM and control) were alpha 1 -adrenergically stimulated with PE (10 µmol/L). Reaching a new steady state, developed forces were measured and normalized to the baseline forces before PEstimulation (relative developed tension, F dev /F 0 ).
Myofilament Ca
2+ responsiveness in semi-skinned muscle fibres
Right ventricular papillary muscles and trabeculae were excised as described above. The muscle strips were split longitudinally in sections measuring about 200-300 µm in width and thickness and 2-4 mm in length.The muscle strips were semi-permeabilized by incubation with 35 µmol/L beta-escin (Sigma-Aldrich) in relaxation solution for 30 min. This technique allows the control of intracellular ion concentrations but maintains sarcolemmal receptors and leaves subcellular signaling mechanisms intact. The muscle strips were mounted for isometric force measurement using aluminum T-clips and stretched to the length at which passive tension just began to increase. Measurements were carried out at room temperature. Relaxation solution contained (in mmol/L): imidazole 20, adenosine triphosphate 10, phosphocreatine 10, NaN 3 5, ethylene glycol-bis-(betaaminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) 5, MgCl 2 12.5. Activation solution additionally contained CaCl 2 at a nominal concentration of 5 mmol/L. The pH of both solutions was adjusted to 6.7 by addition of KOH. Differences in ionic strength between activation and relaxation solutions resulting from different amounts of KOH needed to adjust pH to 6.7 were corrected by adding KCl. Intermediate levels of [Ca 2+ ] were obtained by mixing appropriate amounts of relaxation and activation solutions. The free [Ca 2+ ] was calculated using the computer program WinMAXC (25) (http://www.stanford.edu/~cpatton/maxc.html). The study protocol was adapted to the experiments performed with single myocytes and intact muscle strips. Semi-skinned fibers were preincubated with WM (0.1 µmol/L) or DMSO for 30 min, respectively. Concentration-response curves for Ca 2+ (tensionCa 2+ relationship) were obtained in PE-stimulated semiskinned muscle strips, either with or without WM pretreatment.
Protein expression and phosphorylation level
Western blot analysis were performed as described previously (22, 23) . Briefly, cardiac myocytes were homogenized mechanically in 200 µL ice cold lysis buffer (containing 1% nonidet P 40, 10% glycerol, 137 mmol/L NaCl, 20 mmol/L Tris, pH 7.4, 20 mmol/L NaF, 1 mmol/L Na 3 VO 4 , 1 mmol/L Na 4 P 2 O 7 , 50 mmol/L β-glycerophosphate, 10 mmol/L EDTA, pH 8.0, 1 mmol/L EGTA, pH 7.0, 1 mmol/L phenylmethyl-sulfonyl-fluoride (PMSF), 4 µg/mL aprotinin, 4 µg/mL leupeptin, 4 µg/mL pepstatin). After elimination of the cell debris by centrifugation, protein concentrations in the supernatant were determined by the bicinchoninic acid (BCA) method (Pierce, Bonn, Germany). Proteins were subjected to SDS-PAGE and electroblotted to nitrocellulose membranes. Blots were probed with antibodies against SERCA 2a (Affinity BioReagents, Golden, USA) or phospholamban (PLN, Upstate, Lake Placid, USA) and normalized to glycerol aldehyde phosphate dehydrogenase (GAPDH, Biotrend Chemikalien, Cologne, Germany). Phosphorylation levels were detected with phosphospecific antibodies against PLN-Ser16 and PLN-Thr17 (Badrilla, Leeds, UK). Immunoreactive bands were visualized using enhanced chemiluminescence (Pierce) and quantified by twodimensional scans using a CCD camera system (Multi-Imager, AlphaInnotech Inc., San Leandro, USA).
Statistical Analysis
Data are presented as mean+/-SEM. Differences between experimental groups were evaluated for statistical significance by use of paired or unpaired Student's t-test where appropriate. Every muscle strip experiment followed a paired design with two preparations first dissected from immediately adjacent areas of the same rabbit heart and then examined in parallel in a dual-chamber superfusion system. Therefore, a paired t-test was considered appropriate to assess the level of statistical significance in this data set. EC 50 values of concentration-response curves for Ca 2+ in semi-skinned fibers were compared with extra sum-of-squares F test. A value of P<0.05 was considered significant.
RESULTS
Effect of PI3K inhibition on alpha 1 -adrenergically stimulated single myocytes
In order to sufficiently inhibit PI3K activity, isolated cardiac myocytes were preincubated with WM (0.1 µmol/L) or solvent (DMSO), respectively, for 20 min. Subsequently, electrical field stimulation (1 Hz, 37°C) was started and contractility parameters were analyzed. Basal twitch contraction amplitude (in % of resting cell length) was not significantly altered in WM-treated versus control myocytes (1.91+/-0.19%; n=26 versus 2.01+/-0.21%; n=29; Figure 1 ). The mean resting cell length were 1.87+/-0.01 µm in WM-treated versus 1.85+/-0.01 µm in control myocytes (P=0.33).
After 20 min of incubation with WM, cardiac myocytes were alpha 1 -adrenergically stimulated with PE (10 µmol/L). As expected, both WM-treated and control myocytes exhibited a significant increase in contractility ( Figure 1A) . However, in WM-treated myocytes, PE induced a significantly stronger increase in contractility compared to untreated myocytes (6.14+/-0.33%; n=26 versus 4.85+/-0.33%; n=29, P<0.05; Figure 1A-B) . The mean resting cell length of PE-stimulated myocytes were 1.81+/-0.01 µm in WM-treated versus 1.81+/-0.01 in untreated myocytes (P=0.84).
Effect of PI3K inhibition on alpha 1 -adrenergically stimulated intact muscle strips
Intact multicellular muscle strips were preincubated with WM for 40 min. Compared to the single myocyte experiments the incubation time was doubled to 
Effect of PI3K inhibition on Ca
2+ transients To elucidate the mechanism of the increased contractility in PI3K-inhibited myocardium we analyzed 
Effect of PI3K inhibition on Ca 2+ sensitivity in semiskinned fibres
To analyze the influence of PI3K inhibition on Ca 2+ sensitivity in alpha 1 -adrenergically stimulated myocardium, muscle strips were semi-permeabilized with beta-escin. Figure 4A demonstrates that in alpha 1 -adrenergically stimulated muscle strips the Ca 2+ sensitivity was not affected by inhibition of PI3K. In PE-stimulated muscle strips the EC 50 was 3.37+/-0.22 µmol/L following WM pretreatment versus 3.62+/-0.18 in control fibers (n=5, n.s.). The maximal calcium-activated force was slightly but not significantly increased in WM-treated versus control semi-skinned fibres ( Figure 4B ). Thus, increased contractility by PI3K inhibition is not caused by changes in myofilament Ca 2+ sensitivity.
Effect of PI3K inhibition on protein expression and phosphorylation level
Since inhibition of PI3K increased Ca 2+ transients in alpha 1 -adrenergically stimulated myocytes we investigated its effect on sarcoplasmic reticulum Ca 2+ ATPase (SERCA) and phospholamban (PLN). Incubation with WM (0.1 µmol/L, 20 min) had no effect on protein expression of SERCA and PLN when normalized to GAPDH in PE-stimulated cardiac myocytes (10 µmol/L, 2 min, Figure 5 ). However, Western blot analysis with phosphospecific antibodies revealed a significantly increased phosphorylation level of PLN in WM treated myocytes. PLN-Ser16/PLN and PLN-Thr17/PLN ratio increased by 115+/-19% (n=5, P<0.05) and 53+/-19% (n=5, P<0.05), respectively ( Figure 5 ), indicating higher SERCA activity.
DISCUSSION
In the present study we demonstrate for the first time that inhibition of PI3Ks significantly improves contractility in alpha 1 -adrenergically stimulated myocardium of rabbit hearts and that this effect is mediated by increasing PLN phosphorylation leading to higher intracellular Ca 2+ transients.
These findings are contradictory to studies demonstrating that activation of PI3Ks by overexpression of IGF-1 receptor or IGF-1 infusion has positive inotropic effects and that decreasing PI3K activity by knockout of insulin receptor reduces myocardial contractility (5, 11, 16) .
Differentiating the effects of the distinct isoforms of PI3Ks may help to explain these conflicting results. Four different type I PI3Ks have been described. They are characterized by a 110 kDa catalytic subunit (p110) and are divided into the subclasses IA (PI3Kalpha, PI3Kbeta, PI3Kdelta) and IB (PI3Kgamma). The isoforms PI3Kalpha and PI3Kgamma are of particular importance for the heart (2, 17) . Stimulation of receptor tyrosine kinases (RTK) by IGF-1 or insulin activates the PI3K isoform alpha that is a crucial regulator of cardiac cell size, but also exerts positive inotropic effects due to enhanced Ca 2+ cycling (18) (19) (20) .
On the other hand, PI3K isoform gamma is activated by beta/gamma subunits of G-Proteins and acts downstream of G protein-coupled receptors (GPCRs) as a negative regulator of cardiac contractility (2, 17) . PI3Kgamma-knockout mice display a marked enhancement in contractility as assessed by increased fractional shortening and peak aortic outflow velocity (17) . Mechanistically, Crackower, Oudit et al. were the first demonstrating in an elegant study that PI3Kgamma decreases cardiac contractility by reducing cAMP levels (17) . PI3Kgamma independently of its kinase activity controls PDE3B phosphodiesterase-mediated cAMP destruction (26) . Since cAMP activates PKA which in turn mediates positive chronotropic, inotropic and lusitropic effects via phosphorylation of a variety of target proteins involved in excitation-contraction coupling, reduced cAMP levels result in reduced contractility (27) (28) (29) .
In beta-adrenergically stimulated myocardium, it has been shown that PI3Kgamma modulates particularly beta 2 -signaling. Beta 2 -adrenergic receptors (AR) are coupled to both G alpha/s and G alpha/I G-proteins and thereby either increase (via G alpha/s ) or decrease (via G alpha/i ) cAMP levels and contractility. The opposing effects of these 2 Gprotein subunits neutralize each other, resulting in no global net effect on cAMP levels and cardiac contractility upon receptor stimulation. However, when cardiac myocytes of PI3Kgamma knockout mice are stimulated with a specific beta 2 -AR agonist, increases in cAMP levels and contractility are observed. In contrast, selective beta 1 -AR stimulation does not differentially regulate cAMP levels and contractility in PI3Kgamma null hearts (17) .
Regarding other GPCRs, it has been shown that activation of purinergic receptors (P2 receptor) diminishes Ca 2+ oscillations via PI3Kgamma in neonatal cardiac myocytes while the depression of cardiac function observed in response to platelet-activating factor (PAF), a GPCR agonist released during ischemia, is prevented in PI3Kgamma-null hearts (30) (31) .
In the present study, we demonstrate for the first time that also alpha 1 -AR signaling is modulated by PI3K. Since alpha 1 -AR are GPCRs and inhibition of PI3K increases contractility in alpha 1 -adrenergically stimulated myocardium, the observed effect might be caused by inhibition of PI3K isoform gamma. As a limitation of the present study, wortmannin, the PI3K inhibitor used here, is an unspecific PI3K inhibitor and does not allow us to discriminate between the different isoforms of PI3K.
Under baseline conditions, we found no effect of PI3K inhibition on cardiac contractility. However, with alpha 1 -AR stimulation inhibition of PI3K exerts positive inotropic effects. This could be explained by higher PI3Kgamma activity under alpha 1 -AR stimulation. Comparable to the effects on beta 2 -signaling described above, PI3K activation by alpha 1 -GPCR stimulation counteracts the dominating positive inotropic effect of alpha 1 -signaling. This positive inotropic effect is enhanced by inhibition of PI3K. Mechanistically, we show that in alpha 1 -adrenergically stimulated myocardium PI3K inhibition leads to increased phosphorylation of PLN and higher Ca 2+ transient amplitudes whereas Ca 2+ sensitivity of the myofilaments is not influenced. Since PI3Kgamma is known to reduce cAMP levels, inhibition of PI3K by wortmannin might increase contractility in alpha 1 -stimulated myocardium by increasing cAMP levels with subsequent higher PKA activity. PKA enhances Ca 2+ transients by phosphorylation of L-type Ca 2+ -channels and PLN (at Ser16) thereby increasing I Ca,L and SERCA activity, effectively enhancing contractility (27) (28) (29) . Interestingly, phosphorylation of PLN-Thr17 (CaMKII site) also seems to be increased slightly which may be explained by a secondary effect of increased intracellular Ca 2+ cycling and hence increased CaMKII activation.
Since in human heart failure both the PI3K and the adrenergic signaling system are highly activated, it might be speculated whether inhibition of PI3Kgamma could improve cardiac function in heart-failure patients by modulating alpha 1 -adrenergic signaling (32) (33) (34) . In this regard, it must be critically marked that inhibition of PI3Kgamma increases cAMP signaling as seen with beta-AR agonists and PDE III inhibitors which have proven to be unsuccessful long-term therapies in patients with heart failure (35) . Intriguingly, PI3Kgamma knockout mice are protected from hypertrophy, fibrosis and cardiac dysfunction caused by long-term exposure to the beta-AR agonist isoproterenol, suggesting that inhibition of PI3Kgamma may represent a therapeutic option for the treatment of decreased cardiac function in heart failure (36) .
Although wortmannin, the PI3K inhibitor used in our study, has proven to be cardioprotective in a myocardial ischemia-reperfusion model (37), it is not an ideal compound for in vivo studies or for application in humans since it is also known to be toxic to rats, affecting mainly hepatocytes and the epithelial lining of the gastrointestinal tract (1). Furthermore, PI3Kalpha inhibitors have been considered as anti-cancer agents, but such inhibitors may have adverse effects in the heart (38) . Therefore, a more compatible, isoform-and tissue-specific PI3K inhibitor is required for in vivo studies addressing treatment of heart failure.
In conclusion, this is the first study to demonstrate that inhibition of PI3K improves contractility in alpha 1 -adrenergically stimulated myocardium by increasing PLN phosphorylation and Ca 2+ -transients. This may have clinical implications for the treatment of decreased cardiac function in heart failure. 
